TRILLIUM THERAPEUTICS INC. Research And Development Expense
TRILLIUM THERAPEUTICS INC. reported Research And Development Expense of $27.17 million for the 12-month period ending 2019-12-31, per its 40-F filed 2020-03-10.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2020-03-10
CAD
| Period end | Research And Development Expense 12 month |
|---|---|
| 2018-12-31 | 43.43M CAD 20-F · filed 2019-03-11 |
| 2017-12-31 | 37.13M CAD 20-F · filed 2019-03-11 |
| 2016-12-31 | 29.79M CAD 40-F · filed 2018-04-04 |
USD
| Period end | Research And Development Expense 12 month |
|---|---|
| 2019-12-31 | $27.17M 40-F · filed 2020-03-10 |
| 2018-12-31 | $33.59M 40-F · filed 2020-03-10 |